SYK
STRYKER CORPEvidence as of 2026-09-03Overview · STRYKER CORP
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in…
Management team
- Mr. Preston Wells · VP & CFOFind on LinkedIn
- Mr. Spencer S. Stiles · Group President of Orthopaedics & SpineFind on LinkedIn
- Mr. J. Andrew Pierce · Group President of MedSurg & NeurotechnologyFind on LinkedIn
- Mr. Viju S. Menon · Group President of Global Quality & OperationsFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
−0.3 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The surviving evidence produces a mixed read (Mixed, -0.3 of a possible +2; confidence high). Revenues in Q2 2026 (fiscal quarter ended 2026-06-30) were $ 6,589,000,000, up from $ 6,020,000,000 in Q1 2026 (fiscal quarter ended 2026-03-31) and $ 6,022,000,000 in Q2 2025 (fiscal quarter ended 2025-06-30). Gross profit expanded to $ 4,498,000,000 in Q2 2026 (implying a gross margin near 68.3% versus about 63.3% in Q1 2026), and net income rose to $ 1,276,000,000 in Q2 2026 from $ 745,000,000 in Q1 2026 and $ 884,000,000 in Q2 2025.
Market and valuation signals sit unevenly against those fundamentals: trailing twelve‑month FCF is $ 894,000,000 with FCF per share $ 2.3161 and diluted EPS TTM $ 9.65, while model‑implied FCF growth to justify the price is 0.6378 (63.78%) and price/FCF is 134.79. Volatility is elevated (90‑day annualized +37.3%, volatility at the 99th percentile of the 547‑stock universe), momentum and relative strength metrics are weak (6‑month momentum -17.8%, 6‑month RS vs SPY -29.8%, both low percentile ranks), and the price sits -5.2% versus its 50‑day SMA and -7.6% versus its 200‑day SMA.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenues were $6,589,000,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo), up from $6,020,000,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) and $6,022,000,000 in fiscal Q2 2025 (2025-04-01 to 2025-06-30, 3mo).
XBRL companyfacts · 0000310764-26-000050Gross profit expanded to $4,498,000,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo) from $3,810,000,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo); this implies a gross margin of about 68.3% in fiscal Q2 2026 versus about 63.3% in fiscal Q1 2026 when computed from the reported figures.
XBRL companyfacts · 0000310764-26-000050Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
A Form 4 reporting one or more insider transactions for the company was filed with the 4 filed 20 August 2026 on 2026-08-20 (the evidence record shows the filing entry for that date).
4 filed 2026-08-20A Form 4 reporting one or more insider transactions for the company was filed with the 4 filed 18 August 2026 on 2026-08-18 (the evidence record shows the filing entry for that date).
4 filed 2026-08-18Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
As of 2026-09-02, SYK's 6-month momentum is -17.8% and ranks in the 9th percentile of the 547-stock research universe.
Moneyta signal set · 2026-09-02weakened in debateAs of 2026-09-02, SYK's 3-month momentum is +6.1% while the 12-1 momentum is -10.2% (momentum_12_1 rank: 21th percentile of 547).
Moneyta signal set · 2026-09-02weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02, the iShares Core S&P 500 ETF (IVV) held SYK at 0.17% of fund assets.
ETF constituents · market dataThree Form 4 insider filing events for SYK were submitted in a short span in August 2026 (filed dates: 2026-08-18, 2026-08-20, 2026-08-26).
Form 4 × 3 (90d window not enforced here)Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Several outlets report that Stryker received FDA De Novo authorization for its SportSuite Vision software on Apple Vision Pro and completed the first surgical procedure using that software in an operating room setting.
News · finance.yahoo.com · 2026-09-01Coverage highlights Stryker's use of Apple Vision Pro as a 'surgical cockpit' in connection with the FDA clearance and clinical procedure.
News · statnews.com · 2026-09-01Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Director STRYKER RONDA E reported multiple open-market sales on 18–19 August 2026 totaling about "$111.132M" across "330,276" shares, with the filing's trading-plan field null.
Form 4 · STRYKER RONDA E (Director) · $13k sold · 2026-08-19weakened in debateGroup President Crotty Dylan Bram reported an open-market sale on 21 August 2026 of "$145k" for "441" shares, with the filing's trading-plan field null.
Form 4 · Crotty Dylan Bram (Group President) · $145k sold · 2026-08-21weakened in debateReads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model-implied free cash flow (FCF) growth rate that today’s price would justify under the stated discount and terminal assumptions is 0.6378 (63.78%).
Valuation inputs · SEC XBRL + stored EOD closePrice to trailing twelve‑month FCF is 134.79, which implies the market is valuing current FCF at a very large multiple of present free cash flow.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
The evidence shows improving operating performance: sequential and year-over-year revenue growth (fundamentals-0), a sizable expansion in gross profit and implied gross margin (fundamentals-1), and materially higher quarter-over-quarter net income (fundamentals-2). Reported long-term debt has trended modestly lower (fundamentals-5) while weighted-average diluted shares are roughly stable (fundamentals-4), which together reduce some leverage and dilution concerns. Independent coverage and product milestones — FDA De Novo authorization for SportSuite Vision on Apple Vision Pro and a completed operating-room procedure (news-0, news-1) plus the planned ZuriMED acquisition to expand shoulder-care technology (news-2, news-3) — provide company-specific growth catalysts referenced by multiple outlets and by several sell‑side firms maintaining Buy ratings. Several of the bear points rest on weaker evidence or broader-market observations: elevated short-term volatility and negative 6-month momentum (market-2, market-0) coexist with a very low beta and near-zero correlation to the S&P (market-3), indicating stock-specific news sensitivity rather than pure market beta exposure; the large insider-sale figure (insider-0) is notable but the associated Form 4 records in the filings set show parsing gaps (ownership-2) which weaken the verifiability of that single-data-item narrative. Financial advisors often suggest assessing valuation in context of growth and cash flow dynamics; while headline multiples appear elevated (valuation-1, valuation-2), trailing EPS and FCF per share are positive (valuation-3) and the majority of visible sell‑side coverage is constructive, which collectively supports an educationally favorable read on the company’s operating momentum and strategic positioning.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.31
34 surviving claims rest on 19 distinct sources; the heaviest analyst carries 24% of them, and 91% of what the desk raised survived the debate.
The read rests on a moderate spread of sources but a fairly small number of analysts — one analyst supplies nearly a quarter of surviving claims and most of the desk’s flagged points (91%) survived debate. That pattern increases fragility: the evidence set is informative but somewhat concentrated, so single-source errors or an influential analyst’s mistake would materially change the balance of support for these claims.
Peer context · computed, not argued
12-1 momentum ranks 3rd of 5 in Medical Devices (as of 2026-09-02).
6-month relative strength ranks 4th of 5 in Medical Devices (as of 2026-09-02).
90-day volatility ranks 3rd of 5 in Medical Devices (as of 2026-09-02).
dividend yield ranks 2nd of 5 in Medical Devices (as of 2026-09-02).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
11 filings· 1 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.7 to the score
3 documents· 2 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes+0.0 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash−0.6 to the score
2 holdings records
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis−0.3 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
3 filings· 2 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state — stated and inferred flags kept apart.
Read by Talbot−1.3 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on SYK Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.